-+ 0.00%
-+ 0.00%
-+ 0.00%

Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial

路透·01/07/2026 02:51:15

登錄查看新聞詳情